Hikma Pharmaceuticals PLC (HKMPY)
49.00
-0.02
(-0.03%)
USD |
OTCM |
May 06, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.436B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 8.18% |
| Valuation | |
| PE Ratio | 28.82 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.895 |
| Price to Book Value | 2.473 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.94 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5118 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 64.68% |
Profile
| Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world. |
| URL | https://www.hikma.com |
| Investor Relations URL | https://www.hikma.com/investors |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Aug. 08, 2024 |
| Last Earnings Release | Feb. 22, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 21, 2024 |
Ratings
Profile
| Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world. |
| URL | https://www.hikma.com |
| Investor Relations URL | https://www.hikma.com/investors |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Aug. 08, 2024 |
| Last Earnings Release | Feb. 22, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 21, 2024 |